Madrigal Pharmaceuticals
MDGL
32 hedge funds and large institutions have $23.6M invested in Madrigal Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 3 reducing their positions, and 2 closing their positions.
267% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 3
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
17% more capital invested
Capital invested by funds: $20.1M → $23.6M (+$3.5M)
3% more funds holding
Funds holding: 31 → 32 (+1)
1.59% more ownership
Funds ownership: 11.63% → 13.22% (+1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$788K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$786K |
| 3 |
Millennium Management
New York
|
+$497K |
| 4 |
Goldman Sachs
New York
|
+$328K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$161K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$43.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$724 |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$440 |
MDGL Hedge Fund Activity: Q1 2017 in Review
32 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2017, worth a combined $23.6M — up 17% from $20.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MDGL positions and 2 closed out — a net gain of 4 holders — while 11 added to existing stakes and 3 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $788K. The largest seller was Paloma Partners, exiting entirely with an estimated $161K sold.
- 32 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2017, up from 31 in Q4 2016.
- Funds reported $23.6M of Madrigal Pharmaceuticals stock for Q1 2017, up 17% quarter-over-quarter.
- 6 funds opened new Madrigal Pharmaceuticals positions in Q1 2017 and 2 closed out, a net change of +4 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2017 was Rock Springs Capital Management, an estimated $788K added.
- The largest Madrigal Pharmaceuticals seller in Q1 2017 was Paloma Partners, an estimated $161K sold.
Based on aggregated 13F filings for Q1 2017.